These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 6249243)

  • 1. Prepubertal vaccination of mice against experimental infection of the genital tract with type 2 herpes simplex virus.
    Skinner GR; Williams DR; Moles AW; Sargent A
    Arch Virol; 1980; 64(4):329-38. PubMed ID: 6249243
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Preparation and efficacy of an inactivated subunit vaccine (NFUIBHK) against type 2 Herpes simplex virus infection.
    Skinner GR; Williams DR; Buchan A; Whitney J; Harding M; Bodfish K
    Med Microbiol Immunol; 1978 Nov; 166(1-4):119-32. PubMed ID: 214676
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Protection of guinea pigs against primary and recurrent genital herpes infections by immunization with live heterologous or homologous Herpes simplex virus: implications for a herpes virus vaccine.
    Scriba M
    Med Microbiol Immunol; 1978 Nov; 166(1-4):63-9. PubMed ID: 214688
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Protection from oral herpes simplex virus infection by a nucleic acid-free virus vaccine.
    Kitces EN; Morahan PS; Tew JG; Murray BK
    Infect Immun; 1977 Jun; 16(3):955-60. PubMed ID: 197013
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Recombinant interleukin 2 as an adjuvant for vaccine-induced protection. Immunization of guinea pigs with herpes simplex virus subunit vaccines.
    Weinberg A; Merigan TC
    J Immunol; 1988 Jan; 140(1):294-9. PubMed ID: 2826591
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Protective effect of an oral infection with herpes simplex virus type 1 against subsequent genital infection with herpes simplex virus type 2.
    Sturn B; Schneweis KE
    Med Microbiol Immunol; 1978 Jul; 165(2):119-27. PubMed ID: 209295
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Herpes simplex virus, type II: microbiology and clinical experiences with attenuated vaccine].
    Nasemann T; Schaeg G
    Hautarzt; 1973 Apr; 24(4):133-9. PubMed ID: 4351533
    [No Abstract]   [Full Text] [Related]  

  • 8. Immunized mice challenged with herpes simplex virus by the intranasal route show protection against latent infection.
    Rooney JF; Wohlenberg C; Cremer KJ; Notkins AL
    J Infect Dis; 1989 May; 159(5):974-6. PubMed ID: 2540251
    [No Abstract]   [Full Text] [Related]  

  • 9. Animal studies on the efficacy of vaccination against recurrent herpes.
    Scriba M
    Med Microbiol Immunol; 1982; 171(1):33-42. PubMed ID: 6289061
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy of the herpes simplex virus types 1 and 2 mutant viruses to confer protection against zosteriform spread in mice.
    Mercadal CM; Slaoui M; Brown SM; Rouse BT
    Viral Immunol; 1993; 6(1):35-42. PubMed ID: 8386516
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunogenic properties of formalin herpes antigen prepared from cell cultures.
    Benda R; Dbalý V
    J Hyg Epidemiol Microbiol Immunol; 1973; 17(2):237-49. PubMed ID: 4354219
    [No Abstract]   [Full Text] [Related]  

  • 12. The importance of MHC-I and MHC-II responses in vaccine efficacy against lethal herpes simplex virus type 1 challenge.
    Ghiasi H; Roopenian DC; Slanina S; Cai S; Nesburn AB; Wechsler SL
    Immunology; 1997 Jul; 91(3):430-5. PubMed ID: 9301533
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunogenicity of a subviral herpes simplex type 1 preparation: reduction of recurrent disease in mice.
    Slichtová V; Kutinová L; Vonka V
    Arch Virol; 1982; 71(1):75-8. PubMed ID: 6279057
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mucosal delivery of herpes simplex virus vaccine.
    Bowen JC; Alpar HO; Phillpotts R; Brown MR
    Res Virol; 1992; 143(4):269-78. PubMed ID: 1329168
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Induction and enhancement of immune responses to herpes simplex virus type 2 in humans by use of a recombinant glycoprotein D vaccine.
    Straus SE; Savarese B; Tigges M; Freifeld AG; Krause PR; Margolis DM; Meier JL; Paar DP; Adair SF; Dina D
    J Infect Dis; 1993 May; 167(5):1045-52. PubMed ID: 8387560
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Vaccine potential of a herpes simplex virus type 1 mutant with an essential glycoprotein deleted.
    Farrell HE; McLean CS; Harley C; Efstathiou S; Inglis S; Minson AC
    J Virol; 1994 Feb; 68(2):927-32. PubMed ID: 8289395
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Native herpes simplex virus glycoprotein D vaccine: immunogenicity and protection in animal models.
    Mishkin EM; Fahey JR; Kino Y; Klein RJ; Abramovitz AS; Mento SJ
    Vaccine; 1991 Mar; 9(3):147-53. PubMed ID: 1645898
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hypothetical vaccination of the Dutch population with a herpes simplex virus vaccine: estimation of the profitability using a demographic projection model.
    Bos CA
    Vaccine; 1988 Aug; 6(4):309-14. PubMed ID: 2847437
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunogenicity of subviral herpes simplex virus type 1 preparation: protection of mice against intradermal challenge with type 1 and type 2 viruses.
    Slichtová V; Kutinová L; Vonka V
    Arch Virol; 1980; 66(3):207-14. PubMed ID: 6255896
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prospects for control of herpes simplex virus disease through immunization.
    Stanberry LR; Cunningham AL; Mindel A; Scott LL; Spruance SL; Aoki FY; Lacey CJ
    Clin Infect Dis; 2000 Mar; 30(3):549-66. PubMed ID: 10722443
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.